Development of 1,2,3‐Triazoles as Dual Enzyme Inhibitors Targeting α‐Amylase and α‐Glucosidase for Type 2 Diabetes Intervention
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von K Sruthi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, India. Hauptthemen laut MEDLINE: alpha-Amylases, Diabetes Mellitus, Type 2, Glycoside Hydrolase Inhibitors, alpha-Glucosidases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: This study was supported by VIT SEED GRANT (RGEMS, SG20240009)..
Themen: Diabetes mellitus
Abstract (Originalsprache)
A series of fifteen 1,2,3‐triazole derivatives 6(a–o) were developed and evaluated for their inhibitory effects on carbohydrate‐hydrolyzing enzymes implicated in Type 2 diabetes management. The compounds were assessed through in silico studies (including molecular docking and ADME predictions) and in vitro assays such as α‐amylase, α‐glucosidase, and antioxidant activities. Notably, the compounds 6a , 6d , 6g , 6h , 6k , 6l , and 6n exhibited dual inhibition against both enzymes. Among them, compound 6a exhibited the most potent α‐glucosidase inhibition (IC 50 = 22.15 ± 0.75 µM), comparable to the reference drug acarbose (IC 50 = 21.07 ± 0.05 µM). Meanwhile, compound 6h demonstrated strong α‐amylase inhibition (IC 50 = 84.46 ± 1.14 µM) compared with standard acarbose (IC 50 = 87.62 ± 0.47 µM). Cytotoxicity studies of the most active compounds 6a and 6h indicated moderate cytotoxicity, with IC 50 values of 32.87 ± 1.2 µM and 32.42 ± 1.5 µM, respectively, suggesting a reasonable safety margin compatible with continued drug development. The DPPH assay revealed moderate to good activity for all compounds 6(a–o) , with IC 50 values ranging from 39.60 ± 0.15 to 99.45 ± 0.12 µM. These findings support the therapeutic potential of these compounds as antidiabetic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, India.
ORCID-Profile: S L Manju
Förderung
- This study was supported by VIT SEED GRANT (RGEMS, SG20240009).
Zitieren
APA
Sruthi, K., & Manju, S. L. (2025). Development of 1,2,3‐Triazoles as Dual Enzyme Inhibitors Targeting α‐Amylase and α‐Glucosidase for Type 2 Diabetes Intervention. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70088
Vancouver
Sruthi K, Manju SL. Development of 1,2,3‐Triazoles as Dual Enzyme Inhibitors Targeting α‐Amylase and α‐Glucosidase for Type 2 Diabetes Intervention. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70088
BibTeX
@article{Sruthi2025,
author = {Sruthi, K and Manju, S L},
title = {Development of 1,2,3‐Triazoles as Dual Enzyme Inhibitors Targeting α‐Amylase and α‐Glucosidase for Type 2 Diabetes Intervention},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70088}
}
EUVIMED